Positive preliminary data from SEACRAFT-1, which we reported at the 36 th EORTC-NCI-AACR (ENA) Symposium last month, has refined our clinical development focus of naporafenib plus trametinib on ...

Data presented at SITC follows the Company's presentation at the 36 th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in October 2024. The presentation at SITC titled, 'Phase 1 ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

NXP900, a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines Certain statements in this presentation constitute ...

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association ... Nektar Therapeutics, BionTech Advisory Board: Amgen, Astella ...

“As seen in our presentations at the EORTC-NCI-AACR Symposium, we’ve created a toolbox of integrated approaches to accelerate the discovery and development of transformative degrader medicines.” New ...

1Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University, Tempe, Arizona. 2University of Arizona Cancer Center, Tucson, Arizona. 3University of Arizona College of Medicine, ...

or “fadra”, as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona ...

during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its ...